Revenue

Regeneron Pharmaceuticals·Products & Services·10 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Reimbursement Of Commercialization Related Expenses	$150.8M	$169M	$196.1M	$159.2M	$194M	$182.6M	$193.5M	$184.1M
Reimbursement For Manufacturing Of Commercial Supplies	$157.3M	$175.1M	$169.7M	$165M	$161.5M	$161.5M	$154.3M	$154.3M
Other products	—	—	—	—	—	$800K	$9.3M	$31.3M
(Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net	-$9.1M	-$7.8M	-$11.3M	-$15.5M	-$18M	-$23.5M	-$12.6M	-$16.7M
Lynozyfic	—	—	—	—	—	—	—	$11.2M
Libtayo	$297.4M	$288.6M	$366.9M	$285.1M	$376.5M	—	—	—
Regeneron's share of profits	$988.3M	$1.09B	$1.04B	$1.02B	$1.28B	—	—	—
Total	$3.55B	$3.72B	$3.79B	$3.03B	$3.68B	$3.75B	$3.88B	$3.61B

Collaboration revenueView metric

Product And Service OtherView metric

Other productsView metric

Regeneron's share of profitsView metric

Reimbursement For Manufacturing Of Commercial SuppliesView metric

(Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, netView metric

Reimbursement Of Commercialization Related ExpensesView metric